Clinical trials
Phase 1/2 Heart Diseases trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
18 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 2 |
| 2004 | 1 |
| 2005 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 1 |
| 2019 | 2 |
| 2020 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 7 |
| Terminated | 5 |
| Unknown status | 3 |
| Recruiting | 2 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Alexandra Cristina Senegaglia | 1 |
| Celladon Corporation | 1 |
| CoRepair, Inc. | 1 |
| Cook MyoSite | 1 |
| Foundation for Biomedical Research and Innovation | 1 |
| Institute Arnault Tzanck, France | 1 |
| John J Freiberger | 1 |
| Microvascular Therapeutics, LLC | 1 |
| National Heart and Lung Institute | 1 |
| National Heart, Lung, and Blood Institute (NHLBI) | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Heart Diseases | 18 |
| Cardiovascular Diseases | 8 |
| Heart Failure | 5 |
| Cardiomyopathies | 3 |
| Coronary Artery Disease | 3 |
| Myocardial Infarction | 3 |
| Angina Pectoris | 2 |
| Heart Defects, Congenital | 2 |
| Myocardial Ischemia | 2 |
| Ventricular Dysfunction | 2 |
Trials
Showing 76 to 18 of 18. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.